AskBio

AskBio Announces First Patient Randomized in phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

­ Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in the brain for the treatment of MSA-P Phase 1 randomized, controlled trial to assess safety of AB-1005 delivered to the putamen in patients with MSA-P 17 November 2023 – Research Triangle Park, NC – Asklepios BioPharmaceutical, Inc. (AskBio),...

AskBio Announces First Patient Dosed in Phase 1/Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment of LGMD2I/R9 3 August 2023 -- North Carolina, US -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been dosed in the...
Roslin Innovation Centre Easter Bush Campus Edinburgh, Scotland EH25 9RG

+44 (0) 131 651 9662